Peptides and Weight Loss: What Actually Works, What Doesn't, and How to Think About It

Peptides and weight loss are now inseparably linked in the public conversation — and for good reason. The GLP-1 class has produced the most significant pharmacological weight loss results in clinical history. But that success has also created noise: research peptides marketed alongside approved drugs, mechanism claims that outrun the data, and patients asking practitioners about compounds that have zero human trials.

This guide cuts through that. Here’s the complete evidence landscape, tiered by what we actually know.

---

How Peptides Affect Weight: The Main Mechanisms

Peptides drive weight loss through several distinct biological pathways. Understanding the mechanism matters because it determines who a given compound might benefit — and what the risks are.

GLP-1 Receptor Agonism (appetite and satiety) The most validated mechanism. GLP-1 is a gut hormone that slows gastric emptying, increases insulin secretion, and — critically — acts on the hypothalamus to reduce appetite. Synthetic GLP-1 analogs amplify and extend this signal, producing caloric reduction through appetite suppression rather than stimulant-style thermogenesis.

GH Secretagogue Activity (fat mobilization, body composition) Growth hormone-releasing peptides (GHRPs) and GHRH analogs stimulate GH release. GH is lipolytic — it preferentially mobilizes visceral and subcutaneous fat while preserving lean mass. This makes GH secretagogues useful for body composition change, though they’re not caloric-restriction substitutes.

Direct Lipolytic Activity (fat cell targeting) Some peptides act directly on adipocytes. AOD-9604, the C-terminal fragment of growth hormone, binds fat cell receptors and directly stimulates lipolysis without the anabolic effects of full HGH.

Metabolic Enzyme Inhibition (NAD+ / NNMT pathway) Newer compounds like 5-Amino-1MQ work by blocking NNMT, an enzyme that degrades NAD+ precursors. In preclinical models, this creates a metabolic state resembling caloric restriction — increased fat oxidation, improved insulin sensitivity, preserved muscle mass.

---

Tier 1: FDA-Approved Peptides With Strong Clinical Evidence

Semaglutide (Ozempic / Wegovy)

The current standard for GLP-1 therapy. The STEP trials established 15–17% body weight reduction at 2.4 mg weekly — numbers no oral medication had previously approached. The SELECT cardiovascular outcomes trial added a 20% reduction in MACE in non-diabetic overweight patients, confirming benefit beyond the scale.

Mechanism: GLP-1 receptor agonist (weekly SC injection or daily oral)
Weight loss: 15–17% body weight over 68 weeks
Best for: Patients where appetite suppression and cardiovascular benefit are the primary goals
Limitation: GI side effects during titration; compounding now prohibited following shortage resolution

→ See full semaglutide monograph

Tirzepatide (Mounjaro / Zepbound)

The successor. Tirzepatide adds GIP receptor agonism to GLP-1 agonism, and the combination appears synergistic. SURMOUNT-1 showed 20.9% average body weight reduction at the 15 mg dose — roughly one-third better than semaglutide head-to-head. SURMOUNT-2 and SURMOUNT-3 confirmed durability.

Mechanism: Dual GLP-1/GIP receptor agonist (weekly SC injection)
Weight loss: 15–22.5% body weight depending on dose
Best for: Patients who need maximum weight loss efficacy; those with concurrent T2D
Limitation: Higher cost; cardiovascular outcomes trial still ongoing

→ See full tirzepatide monograph

Tesamorelin (Egrifta)

FDA-approved specifically for visceral adiposity reduction in HIV-associated lipodystrophy. Tesamorelin is a GHRH analog — it stimulates GH release, which preferentially targets visceral fat. Phase II trials are evaluating it for NASH in the general population, which would broaden its approved use significantly.

Mechanism: GHRH analog → GH pulse stimulation → visceral lipolysis
Weight loss: Not a body weight reducer; specific to visceral fat reduction
Best for: Visceral adiposity, metabolic syndrome, practitioners seeking a GH mechanism with an approved track record
Limitation: Narrow approved indication; off-label use requires informed consent

→ See full tesamorelin monograph

---

Tier 2: Restricted Peptides With Moderate Evidence

CJC-1295 + Ipamorelin Stack

These are the most commonly prescribed GH secretagogues outside of tesamorelin. CJC-1295 is a GHRH analog (long-acting); ipamorelin is a selective GHRP. Combined, they produce synergistic GH release. Human pharmacokinetic trials exist for both. The weight loss data is indirect — practitioners observe body composition changes (fat reduction, muscle preservation) consistent with elevated GH, but purpose-designed weight loss trials are absent.

FDA restricted compounding of both following 2023 actions. Access has narrowed significantly since.

Mechanism: GHRH analog + GHRP → GH secretion → lipolysis
Evidence level: Moderate (PK/PD data; indirect body composition evidence)
Regulatory status: Restricted — not currently available through licensed 503A compounding
Best for: Body composition recomposition, not primary obesity treatment

→ CJC-1295 monograph | Ipamorelin monograph

---

Tier 3: Research-Stage Compounds — Preclinical Evidence Only

AOD-9604

AOD-9604 is the C-terminal GH fragment (amino acids 177–191), modified for stability. It completed a Phase 3 obesity trial — which did not hit primary endpoints on weight loss — but animal data on direct lipolysis remains interesting. It subsequently received FDA GRAS status in the context of food additives, which is a narrow and often-misrepresented finding.

The compound is not FDA-approved, not on the 503A list, and the Phase 3 failure is a significant data point that the research peptide market consistently minimizes.

Mechanism: Direct adipocyte receptor binding → lipolysis (without HGH anabolic effects)
Evidence level: Preliminary — strong animal data, Phase 3 human trial did not reach primary endpoint
Regulatory status: Research-only
Bottom line: The mechanism is real; the human efficacy evidence is not there yet

→ See full AOD-9604 monograph

5-Amino-1MQ

5-Amino-1MQ is a small-molecule NNMT inhibitor, technically a methylquinolinium compound rather than a peptide in the traditional sense. Preclinical data in rodent models shows significant fat mass reduction and preserved lean mass without caloric restriction. The NAD+ pathway mechanism is biologically plausible and generates legitimate scientific interest.

Human data: none yet. Dosing in humans is extrapolated from animal studies. It’s being used clinically by some longevity practitioners, but any practitioner recommending it should be clear that they’re operating outside any established evidence base.

Mechanism: NNMT inhibition → NAD+ preservation → metabolic shift toward fat oxidation
Evidence level: Preliminary — preclinical only
Regulatory status: Research-only
Bottom line: Plausible mechanism, no human data, use with eyes open

→ See full 5-Amino-1MQ monograph

---

What This Looks Like in Practice

For primary obesity treatment: GLP-1 receptor agonists are the evidence-backed choice. Semaglutide or tirzepatide, depending on the patient profile. Nothing else in this space approaches their magnitude of effect.

For body composition (fat loss with muscle preservation): GH secretagogues — tesamorelin (approved) or CJC-1295/ipamorelin (where legally accessible) — address the visceral/subcutaneous fat compartment while preserving lean mass. Different mechanism, different patient.

For the research-curious patient: AOD-9604 and 5-Amino-1MQ have plausible biology and limited human risk signals. But both require an honest informed consent conversation: the human efficacy data is not there. “I’m prescribing this because the mechanism is interesting and the risk profile appears low” is a defensible position. “This is proven to burn fat” is not.

---

What to Watch

The July 2026 FDA advisory panel reviewing seven peptides — including compounds in the GH secretagogue class — could meaningfully change the regulatory landscape. If that panel moves any compound toward the 503A list, access will broaden. If it goes the other way, it narrows further.

Retatrutide (GLP-1/GIP/glucagon triple agonist, Phase 3) is showing 24%+ weight loss in early data and will likely reshape the GLP-1 class again within 12–18 months.

→ FDA Advisory Panel Preview: July 2026